Scientific Agenda

Saturday, December 5, 2009

Clinical Track

8:00 am Welcome
Richard P. MacDermott, MD, FACG and Stephen B. Hanauer, MD, FACG

Research Track

8:00 am Welcome
Lloyd Mayer, MD and
R. Balfour Sartor, MD

Parallel Sessions:
8:10 am - 10:00 am

Session V A: Challenges in clinical research in IBD
Parallel with Research Track V B
Co-moderators: Stephen B. Hanauer, MD, FACG and William J. Sandborn, MD, FACG
8:10 am What the clinician needs to know about the basic science of IBD
Maria T. Abreu, MD
8:30 am Gazing into the crystal ball: New biologics in development
Speaker invited
8:50 am Introduction to quality of care for IBD
Corey A. Siegel, MD
9:10 am Unresolved clinical research questions in IBD
Bruce E. Sands, MD, FACG
9:30 am Panel discussion
10:00 am Coffee break and poster viewing

Session V B: State of the Art in Immune Regulation in IBD
Parallel with Clinical Track V A
Co-Moderators: Theresa Pizarro, PhD and Scott Plevy, MD
8:10 am Understanding the clinical aspects of Crohn’s disease and ulcerative colitis: Implications for the basic scientist
Scott E. Plevy, MD
8:30 am Advances in the understanding the IL-23/Th17 axis in IBD
Casey T. Weaver, MD
8:50 am Regulatory pathways in IBD
Scott Snapper, MD, PhD
9:10 am Epithelial cell activation of novel regulatory cells
Lloyd Mayer, MD
9:30 am Panel discussion
10:00 am Coffee break and poster viewing
 

Parallel Sessions:
10:30 am - 12:30 pm

Session VI A: Debates: Current controversies in IBD
Parallel with Research Track VI B
Co-moderators: Asher A. Kornbluth, MD and William J. Tremaine, MD, FACG
10:30 am Pro: Biologics should be used as monotherapies in Crohn’s disease
Stephen B. Hanauer, MD, FACG
10:45 am Con: Immunomodulators should be used in combination with biologics in Crohn’s disease
William J. Sandborn, MD, FACG
11:00 am Panel discussion
11:10 am Pro: The risk of lymphoma should influence the choice of therapy
Joel R. Rosh, MD, FACG
11:25am Con: the risk of lymphoma should influence the choice of therapy
James D. Lewis, MD, MSCE
11:40 am Panel discussion
11:50 am Pro: Ulcerative colitis patients with low grade dysplasia should undergo colectomy
Thomas A. Ullman, MD, FACG
12:05 pm Con: Ulcerative colitis patients with low grade dysplasia should undergo frequent surveillance colonoscopies
David T. Rubin, MD, FACG
12:20 pm Panel discussion
12:30 pm Lunch satellite symposium

Session VI B: Basic Research Meet the Professor Seminars
All talks are 45 minutes, begin at 10:30 am and repeat at 11:30 am
Parallel with Clinical Track VI A
10:30 am Unanswered research questions in epithelial cell biology
Sean P. Colgan, PhD,Lloyd Mayer, MD and Charles Parkos, MD
Unanswered research questions in animal models of IBD
Matthew B. Grisham, PhD, Charles O. Elson III, MD, and D. Brent Polk. MD
Unanswered research questions regarding regulation of inflammation in IBD
Christian Jobin, PhD, Scott Snappper, MD and Theresa Pizarro, PhD
11:15 am Move to second breakout
11:30 am Unanswered research questions in epithelial cell biology
Sean P. Colgan, PhD,Lloyd Mayer, MD and Charles Parkos, MD
Unanswered research questions in animal models of IBD
Matthew B. Grisham, PhD, Charles O. Elson III, MD, and D. Brent Polk. MD
Unanswered research questions regarding regulation of inflammation in IBD
Christian Jobin, PhD, Scott Snappper, MD and Theresa Pizarro, PhD
12:15 am Lunch break
 

Parallel Sessions:
2:00 pm- 3:45 pm

Session VII A: Case based break out sessions
All talks are 45 minutes, begin at 2:00 pm and repeat at 3:00 pm
Parallel with Research Track VII B

Attendees are welcome to and encouraged to bring cases from their practice for discussion.
2:00 pm Treating the challenging inpatient with complicated IBD: Case studies
Stephen B. Hanaver, MD, FACG and Daniel H. Present, MD, FACG
Extraintestinal manifestations: Case studies
Robert Burakoff, MD, FACG and William J. Tremaine, MD, FACG
Diagnosis and treatment of gastrointestinal tract infections: Case studies
Leonard Baidoo, MD and David G. Binion, MD
Complications of the rectum and J-pouch in IBD: Case studies
Gary R. Lichtenstein, MD, FACG and Bo Shen, MD, FACG
An ounce of prevention is worth a pound of cure: The importance of health care maintenance in IBD: Case studies
Sunanda V. Kane, MD, FACG and Uma Mahadevan, MD
2:45 am Move to second breakout
3:00 pm Treating the challenging inpatient with complicated IBD: Case studies
Stephen B. Hanaver, MD, FACG and Daniel H. Present, MD, FACG
Extraintestinal manifestations: Case studies
Robert Burakoff, MD, FACG and William J. Tremaine, MD, FACG
Diagnosis and treatment of gastrointestinal tract infections: Case studies
Leonard Baidoo, MD and David G. Binion, MD
Complications of the rectum and J-pouch in IBD: Case studies
Gary R. Lichtenstein, MD, FACG and Bo Shen, MD, FACG
An ounce of prevention is worth a pound of cure: The importance of health care maintenance in IBD: Case studies
Sunanda V. Kane, MD, FACG and Uma Mahadevan, MD
3:45 pm Coffee break and poster viewing

Session VII B: Animal models of IBD
Parallel with Clinical Track VII A
Co-moderators: Christian Jobin, PhD, and Theresa Pizarro, PhD
2:00 pm Advances in animal models of immune dysregulation in IBD Charles O. Elson III, MD
2:20 pm Question and answer
2:25 pm Cytokine-mediated inflammation in animal models of IBD
Theresa Pizarro, PhD
2:45 pm Question and answer
2:50 pm Use of animal models for therapeutic intervention studies in IBD
Matthew B. Grisham, PhD
3:10 pm Question and answer
3:15 pm Epithelial cell repair and tumorigenesis in animal models of IBD
D. Brent Polk, MD
3:35pm Question and answer
3:40 pm Coffee break
 

Parallel Sessions:
4:00 pm - 5:25 pm

Session VIII A: Advances in the management of IBD – II
Parallel with Research Track VIII B
Parallel with Nursing Symposium VIII C
Parallel with Pediatric IBD Track VIII D
Co-Moderators: David G. Binion, MD and Robert Burakoff, MD, FACG
4:00 pm Use of TPMT and metabolites to optimize 6-MP and AZA dosing
Marla C. Dubinsky, MD
4:20 pm Question and answer
4:25 pm Use of probiotics and complementary medical therapy
William J. Tremaine, MD, FACG
4:45 pm Question and answer
4:50 pm What endpoints of therapy should we use in clinical practice?
Gary R. Lichtenstein, MD, FACG
5:10 pm Question and answer
5:15 pm Presentation of two research abstracts

PROTECT-1 maintenance phase study results demonstrate efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet EN) in Chron's disease
Pirow Bekker, MD, PhD

Need for rescue therapy in IBD patients on infliximab maintenance therapy after discontinuation of immunomodulator
Monika Fischer, MD
5:40 pm Adjourn

Session VIII C: Nursing Symposium Track VIII C
Parallel with Clinical Track VIII A
Parallel with Research Track VIII B
Parallel with Pediatric IBD Track VIII D
Moderator: Jan Colwell, RN, MS, CWOCN, FAAN
4:00 pm Wound management in the patient with inflammatory bowel disease
Nancy Tomaselli, RN, MSN, FNP, CWOCN
4:25 pm Interactive case presentation
4:35 pm Question and answer
4:40 pm Problem solving for the IBD patient with a fecal diversion
Jan Colwell, RN, MS, CWOCN, FAAN
5:05 pm Interactive case presentation
5:15 pm Question and answer
5:20 pm Adjourn

Session VIII D: Pediatric IBD Track VIII D
Parallel with Clinical Track VIII A
Parallel with Research Track VIII B
Parallel with Nursing Symposium Track VIII C
Co-moderators: Robert N. Baldassano, MD and Francisco A. Sylvester, MD
4:00 pm Enteral therapy for pediatric IBD Robert N. Baldassano, MD
4:20 pm Do pediatric IBD patients need more aggressive treatment than we currently are using?
Francisco A. Sylvester, MD
4:40 pm Debate: Current controversy in pediatric IBD Pro: The best maintenance therapy in pediatric IBD is an immunomodulator
Marla C. Dubinsky, MD
5:00 pm Con: The best maintenance therapy in pediatric IBD is a biologic
Joel R. Rosh, MD, FACG
5:20 pm Abstract presentations

Improved outcomes in quality improvement collaborative for pediatric Chron's disease
Wallace Crandall, MD

Immunogenicity of influenza vaccination in children with inflammatory bowel disease
Jennifer deBruyn, MD
5:40 pm Adjourn

IBD Research Track VIII B
Session II B: Mechanisms of inflammation in IBD
Parallel with Clinical Track VIII A
Parallel with Nursing Symposium Track VIII C
Parallel with Pediatric IBD Track VIII D
Co-Moderators: Sean P. Colgan, PhD and Matthew B. Grisham, PhD

4:00 pm Role of neutrophils in IBD
Charles Parkos, MD
4:20 pm Question and answer
4:25 pm NFkB and NoD2 signalling in IBD
Christian Jobin, PhD
4:45 pm Question and answer
4:50pm Macrophages in IBD
Scott E. Plevy, MD
5:10 pm Question and answer
5:15 pm Presentation of two research abstracts

TLR2 - mediated control of gap junctional intercellular communication essentially contributes to intestinal epithelial barier homeostasis during acute and chronic colitis
Elke Cario, MD

CCR9 inhibition in the treatment of colonic inflammation
Matthew Walters, PhD
5:50 pm Adjourn